OnKure Therapeutics, Inc. (NASDAQ:OKUR – Get Free Report) shares crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.71 and traded as high as $2.81. OnKure Therapeutics shares last traded at $2.75, with a volume of 682,257 shares trading hands.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on OKUR. Weiss Ratings downgraded shares of OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 10th. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price objective on shares of OnKure Therapeutics in a research report on Friday, August 14th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $17.50.
Check Out Our Latest Research Report on OnKure Therapeutics
OnKure Therapeutics Price Performance
The firm has a 50-day moving average of $2.69 and a 200-day moving average of $3.59.
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. On average, equities analysts anticipate that OnKure Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.
Hedge Funds Weigh In On OnKure Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Vivo Capital LLC purchased a new stake in OnKure Therapeutics during the first quarter valued at $7,981,000. Seven Fleet Capital Management LP purchased a new position in OnKure Therapeutics in the second quarter worth about $1,099,000. Renaissance Technologies LLC increased its position in shares of OnKure Therapeutics by 52.5% during the 1st quarter. Renaissance Technologies LLC now owns 377,250 shares of the company’s stock valued at $1,562,000 after purchasing an additional 129,900 shares during the last quarter. ADAR1 Capital Management LLC increased its position in shares of OnKure Therapeutics by 140.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after purchasing an additional 1,420,783 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of OnKure Therapeutics during the 1st quarter valued at about $998,000. 90.98% of the stock is owned by institutional investors.
About OnKure Therapeutics
OnKure Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer. Its research centers on targeted therapies designed to address molecular changes that can drive tumor growth. The company’s pipeline includes OKI-219, an investigational small-molecule therapy designed to selectively inhibit a mutant form of PI3Kα. OnKure has also worked on drug candidates targeting epigenetic mechanisms involved in cancer, reflecting its broader focus on developing treatments against specific cancer-related targets.
See Also
- Five stocks we like better than OnKure Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
